Skip to content

Feasibility Trial of CBT for Depersonalisation in Psychosis

A Brief Cognitive Behavioural Therapy (CBT) Intervention for Depersonalisation/Derealisation in Psychosis: a Feasibility Study

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02427542
Enrollment
20
Registered
2015-04-28
Start date
2015-03-31
Completion date
2016-03-31
Last updated
2016-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depersonalization, Psychotic Disorders

Keywords

Randomized Controlled Trial

Brief summary

This is a feasibility trial designed to test the feasibility and acceptability of a brief form (six sessions) of Cognitive Behavioural Therapy (CBT) for Depersonalisation/Derealisation (DP/DR) in those individuals who also have a diagnosis of a psychotic disorder. Participants will be randomised to receive either six sessions of CBT targeting DP/DR symptoms or to a treatment as usual control condition.

Detailed description

Depersonalisation/derealisation (DP/DR) are distressing symptoms of having a sense of detachment and unreality about oneself (DP) or the external world (DR). Cognitive Behavioural Therapy (CBT) has been found to be beneficial in treating patients with chronic DP/DR. CBT for DP/DR includes educating patients about these experiences so they have a better understanding and less fear; teaching ways of coping to help them manage the symptoms better; helping reduce the impact on their day to day functioning; and working together to find less distressing ways of interpreting these experiences. Recent research has highlighted that DP/DR symptoms are common in people diagnosed with psychotic disorders, and when present are linked with more severe psychotic symptoms. However, there has been no previous study to ascertain if CBT to target DP/DR in psychosis would be effective. This study therefore aims to establish the feasibility of a brief CBT intervention for DP/DR in people diagnosed with a psychotic disorder. It is hoped that the CBT will reduce the distress associated with DP/DR experiences, with a possibility of reducing psychotic phenomena in addition. The investigators will seek to recruit adults aged 18-70 with a current psychotic symptoms as well as meeting threshold for DP/DR disorder. Participants will be randomly assigned to receive six sessions of CBT or to a treatment as usual control. Outcomes will be assessed at baseline and follow-up interview at 10 weeks.

Interventions

OTHERCBT for Depersonalization/Derealization

In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.

OTHERTreatment as usual

Treatment as usual - in most cases case management/care coordination and may include medication

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* current experience of psychotic symptoms, * meeting threshold for DP/DR disorder (scores greater than 70 on Cambridge Depersonalization Scale (CDS)).

Exclusion criteria

* insufficient capacity to provide informed consent; * insufficient proficiency in English (spoken and written) to engage in CBT; * a primary diagnosis of intellectual disability, head injury, substance misuse or organic cause for psychosis; * those currently engaging in CBT or other psychotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of intervention ( including recruitment rates, acceptance rates, drop outs)10 weeksFeasibility estimates of delivering the intervention including recruitment rates, acceptance rates, drop outs.
Depersonalisation score (Score on the Cambridge Depersonalisation Scale)10 weeksScore on the Cambridge Depersonalisation Scale
Acceptability of intervention (Satisfaction and attrition rates)10 weeksSatisfaction and attrition rates

Secondary

MeasureTime frameDescription
Depression (Score on Beck Depression Inventory)10 weeksScore on Beck Depression Inventory
Anxiety (Score on Beck Anxiety Inventory)10 weeksScore on Beck Anxiety Inventory
Psychosis (Score on the Psychotic Symptom Rating Scale (PSYRATS)10 weeksScore on the Psychotic Symptom Rating Scale (PSYRATS)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026